HOM-TES-103 Inhibitors
HOM-TES-103 inhibitors encompass a range of compounds that, through their distinct mechanisms of action, can lead to the reduced activity of HOM-TES-103. These compounds do not directly target HOM-TES-103 but intervene in the signaling pathways and cellular processes that regulate its function. For example, inhibitors like staurosporine and dasatinib interfere with kinase signaling that HOM-TES-103 may depend upon. If HOM-TES-103's activity is contingent on phosphorylation events catalyzed by specific kinases, then staurosporine's broad kinase inhibition profile could lead to an indirect decrease in HOM-TES-103 activity by preventing necessary phosphorylation events. Similarly, dasatinib's inhibition of BCR-ABL and Src family kinases would lead to decreased activity of HOM-TES-103 if tyrosine kinase signaling from these kinases is required for its activity.
Likewise, compounds such as LY294002 and wortmannin target the PI3K/Akt pathway. If the activity of HOM-TES-103 is PI3K/Akt-dependent, inhibition by these compounds would lead to a decrease in HOM-TES-103 activity by reducing the downstream signaling cascade necessary for HOM-TES-103 activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that broadly targets several kinases. By inhibiting protein kinase C (PKC), which can phosphorylate and modulate the activity of many proteins, staurosporine can indirectly inhibit HOM-TES-103 if PKC phosphorylation is necessary for HOM-TES-103's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is part of two complexes, mTORC1 and mTORC2, involved in protein synthesis and cytoskeletal organization. Inhibition of mTOR could reduce the activity of HOM-TES-103 if it is involved in these cellular processes regulated by mTOR. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that alters chromatin structure and affects gene expression. If HOM-TES-103 function is contingent on a specific state of chromatin, this compound could indirectly inhibit its activity by changing gene expression profiles. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If HOM-TES-103's activity requires the proteasomal degradation of certain regulatory proteins, bortezomib could indirectly inhibit HOM-TES-103 by stabilizing those proteins. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets BCR-ABL and Src family kinases. If HOM-TES-103 activity is regulated by tyrosine phosphorylation through these kinases, dasatinib could indirectly inhibit its activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets RAF kinases in the RAS/RAF/MEK/ERK signaling pathway. If HOM-TES-103 is regulated downstream of this pathway, inhibition of RAF kinases could indirectly inhibit the activity of HOM-TES-103. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide binds to the E3 ubiquitin ligase complex and modulates degradation of specific proteins. If HOM-TES-103 requires the ubiquitination of certain substrates for its function, thalidomide could indirectly inhibit its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can suppress the PI3K/Akt pathway. If the activity of HOM-TES-103 is PI3K/Akt-dependent, inhibition by LY294002 could lead to a decrease in HOM-TES-103 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that prevents activation of the MAPK/ERK pathway. If HOM-TES-103 operates downstream of ERK, its activity could be indirectly inhibited by the action of PD98059. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If HOM-TES-103 is regulated by p38 MAPK-dependent signaling, inhibition by SB203580 could lead to a reduction in HOM-TES-103 activity. | ||||||